Authors
Latest:
Exploring Preliminary Results of Ibrutinib and Fludarabine in CLLChristopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Latest:
Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBCRuta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Latest:
Neoadjuvant Immunotherapy Expands Its Reach in Metastatic MelanomaA number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.
Latest:
Treatment Options After Relapse in CLLWojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.
Latest:
ALPINE Trial Shows Zanubrutinib Outperforms Ibrutinib in CLL/SLLHabte Yimer, MD, provides an overview of the ALPINE trial of zanubrutinib vs ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Prior Pluvicto Shortage Led to Long Waiting Lists for Patients With mCRPCRoby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Latest:
Azacitidine Plus APR-246 Appears Promising as Treatment of TP53-Mutant MDS and AMLThomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Latest:
Patients Are Ready for Personalized Health Care, and the Data DeliversDevices like smart blood pressure cuffs, scales, and even smartphones with health sensors are turning our daily routines into personalized health insights.
Latest:
New Pathways for Oncolytic Virals in Breast CancerJohanna Kaufmann, PhD, discusses promising preclinical findings on first-in-class oncolytic viral therapy in breast cancer treatment.
Latest:
Future Directions in GVHDPashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.
Latest:
Integrating Personalized Medicine: Advice for Medical OncologistsTracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.
Latest:
Treatment Failure in CML: Distinguishing Between Disease Resistance and Treatment IntolerancePatients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.
Latest:
Evaluating Current Challenges in Hepatocellular CarcinomaAnjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.
Latest:
Ever-Changing Treatment Landscape of Aggressive B-Cell LymphomaJason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Latest:
Revised Panobinostat Combination Shows Efficacy in Multiple MyelomaAndrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.
Latest:
Ide-Cel Shows Benefit for Multiple Myeloma After 2 to 4 Lines of TherapyAbdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Latest:
Evaluating the Impact of Genetic Mutations on Prostate Cancer Survival RatesRohan Garje, MD, provides an overview of a study evaluating how mutations, including TP53, RB1, and PTEN, impact overall survival in patients with metastatic prostate cancer.
Latest:
Outpatient Cilta-cel for Relapsed/Refractory Multiple MyelomaTaiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma.
Latest:
Cho Provides Background on the Multiple Myeloma Research Foundation’s CureCloud StudyHearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.
Latest:
Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to EfficacySamer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.
Latest:
Targeting PIK3CA Mutations in Breast CancerAndreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors.
Latest:
Breakthrough in TNBC Treatment: Avelumab Extends Overall SurvivalPierfranco Conte, MD, discusses findings and implications of the A-BRAVE study.
Latest:
Key Takeaways on Recent Data in Breast Cancer from SABCS 2023Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in breast cancer.
Latest:
Elacestrant Outperforms SOC in Terms of PFS in ER+/HER2– mBCPatients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.
Latest:
World Cancer Day: Next Generation Sequencing at the Forefront of Precision MedicineNext generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.
Latest:
Transforming Prostate Cancer Care Through Personalized MedicineAdam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
